This review focuses on emerging abbreviated magnetic resonance imaging (AMRI) surveillance of patients with chronic liver disease for hepatocellular carcinoma (HCC). This surveillance strategy has been proposed as a high-sensitivity alternative to ultrasound for identification of patients with early-stage HCC, particularly in patients with cirrhosis or obesity, in whom sonographic visualization of small tumors may be compromised. Three general AMRI approaches have been developed and studied in the literature - non-contrast AMRI, dynamic contrast-enhanced AMRI, and hepatobiliary phase contrast-enhanced AMRI - each comprising a small number of selected sequences specifically tailored for HCC detection. The rationale, general technique, advantages and disadvantages, and diagnostic performance of each AMRI approach is explained. Additionally, current gaps in knowledge and future directions are discussed. Based on emerging evidence, we cautiously recommend the use of AMRI for HCC surveillance in situations where ultrasound is compromised.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- public health
- diffusion weighted
- computed tomography
- early stage
- diffusion weighted imaging
- magnetic resonance
- metabolic syndrome
- healthcare
- systematic review
- insulin resistance
- clinical trial
- weight loss
- current status
- adipose tissue
- smoking cessation
- radiation therapy
- neoadjuvant chemotherapy
- dual energy
- high fat diet induced